IGF1R encodes insulin like growth factor 1 receptor (1,367 aa). Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. Highest expression in Artery Tibial (41.2 TPM) and Ovary (34.9 TPM).

Growth delay due to insulin-like growth factor I resistance is associated with mutations in the IGF1R gene on chromosome 15.

IGF1R is classified as a druggable target (Clinically Actionable, Druggable Genome, Kinase, and Tyrosine Kinase categories) with score 4.2.

Genetic testing for IGF1R is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for growth delay due to insulin-like growth factor I resistance has been reported in the published literature.

Phenotype severity distribution: 1 very common feature, 6 common features.

Estimated prevalence: Unknown (Unknown prevalence).

3 clinical trials registered. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.

106 publications have been identified in PubMed for growth delay due to insulin-like growth factor I resistance. Research spans Review / Meta-Analysis (39%), Basic Science / Preclinical (28%), and Clinical Trial Publication (14%).

Recent Publications

• Pascual-Corrales E (2026). [PMID: 41912300](https://pubmed.ncbi.nlm.nih.gov/41912300/). *Vitam Horm*. [Review / Meta-Analysis]

• Lin W (2026). [PMID: 40569033](https://pubmed.ncbi.nlm.nih.gov/40569033/). *J Clin Endocrinol Metab*. [Diagnostic / Biomarker]

• Dong C (2026). [PMID: 41501017](https://pubmed.ncbi.nlm.nih.gov/41501017/). *Nat Commun*. [Epidemiology / Natural History]

• Gao J (2026). [PMID: 41352341](https://pubmed.ncbi.nlm.nih.gov/41352341/). *Cell Metab*. [Basic Science / Preclinical]

• Bong D (2026). [PMID: 41390120](https://pubmed.ncbi.nlm.nih.gov/41390120/). *Mol Cells*. [Review / Meta-Analysis]

• Xenos D (2026). [PMID: 41275975](https://pubmed.ncbi.nlm.nih.gov/41275975/). *Ageing Res Rev*. [Review / Meta-Analysis]

• Dani C (2026). [PMID: 42177039](https://pubmed.ncbi.nlm.nih.gov/42177039/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]

• Solé G (2026). [PMID: 41951495](https://pubmed.ncbi.nlm.nih.gov/41951495/). *Rev Med Interne*. [Review / Meta-Analysis]

• Iglesias P (2026). [PMID: 41912291](https://pubmed.ncbi.nlm.nih.gov/41912291/). *Vitam Horm*. [Review / Meta-Analysis]

• Gatto F (2026). [PMID: 41569446](https://pubmed.ncbi.nlm.nih.gov/41569446/). *Pituitary*. [Review / Meta-Analysis]